Changes in epidemiology and clinical characteristics of cervical cancer over the past 50 years

Abstract

Abstract: Objective To evaluate the changes in the epidemiology and clinical characteristics of cervical cancer over the past 50 years, and explore appropriate treatment corresponding to these changes. Methods The clinical and pathological data of 1557 patients with invasive cervical cancer treated between January, 1955 and December, 2004 were retrospectively analyzed. Results and Conclusions The average age of cervical cancer onset gradually decreased over the past 50 years, from 56.27±8.45 in 1955-1964 to 43.81±8.9 years in 1995-2004, whereas the ratio of young (≤35 years old) patients rose from 3.42% to 24.91%. The ratio of early clinical stage (stagesⅠ-Ⅱ) and non-squamous cancer also steadily increased (P<0.05, respectively). The tumor stage, pathological type and rate of lymph node metastasis were all significantly different among different age groups (P<0.05). In particular, the young (≤35 years old) group had evidently higher ratios of non-squamous and advanced stage (Ⅲ-Ⅳ) cancers with a higher rate of lymphatic metastasis in comparison with other age groups (P<0.01, respectively). Because of the changes in epidemiology and clinical characteristics of cervical cancer, it is necessary to modify the conventional treatment regimens and explore reasonable therapy corresponding to these changes. Preservation of reproductive endocrine function ought to be fully considered in cervical cancer treatment in women at childbearing age. Neoadjuvant intraarterial chemotherapy is an useful method for cervical cancer treatment at present.

CLC Number:

R737.33

ZHAO En-feng¹, BAO Lei², LI Chao, SONG Lei³, LI Ya-li¹. Changes in epidemiology and clinical characteristics of cervical cancer over the past 50 years[J]. Journal of Southern Medical University, 2005, 25(06): 605-609.

References

[1] Piver MS, Rutledge F, Smith JP. Five classes of extened hysterectomy[J]. Obstet Gynecol, 1974, 44(2):265-9.
[2] Ito T, Ishizuka T, Suzuki K, et al. Cervical cancer in young Japanese women[J]. Arch Gynecol Obstet, 2000, 264(1):68-70.
[3] Clark MA, Naahas W, Marker RJ, et al. Cervical cancer:women aged 35 and younger compared to women aged 36 and older [J].Am J Clin Oncol, 1991, 14(2):352-6.
[4] Cuzick J, Sasieni P, Singer A. Risk factors for cervix cancer in young women[J]. Eur J Cancer, 1996, 32A(3):836-41.
[5] Creasman WT, Zaino RJ, Major FJ, et al. Early invasive carcinoma of the cervix (3 to 5 mm invasion):risk factors and prognosis. A Gynecologic Oncology Group study [J]. Am J Obstet Gynecol,1998, 178(1):62-5.
[6] Dargent D, Martin X, Sacchetoni A, et al. Laparoscopic vaginal radical trachelectomy:a treatment to preserve the fertility of cervical carcinoma patients[J]. Cancer, 2000, 88(4):1877-82.
[7] Schlaerth JB, Spirtos NM, Schlaerth AC. Radical trachelectomy and pelvic lymphadenectomy with uterine preservation in the treatment of cervical cancer[J]. Am J Obstet Gynecol, 2003, 88(1):29-32.
[8] Lee CL, Huang KG, Wang CJ, et al. Laparoscopic radical trachelectomy for stage Ⅰ bl cervical cancer [J]. J Am Assoc Gynecol Laparosc, 2003, 10(1):111-5.
[9] Yamamoto R, Okamoto K, Yukiharu T, et al. A study of risk factors for ovarian metastases in stage Ⅰ b-Ⅲ b cervical carcinoma and analysis of ovarian function after a transposition [J]. Gynecology,2001, 82(3):312-6.
[10] Olejek A, Wala D, Chimiczewski P, et al. Hormonal activity of transposed ovaries in young women treated for cervical cancer [J].Gynecol Endocrinol, 2001, 15(1):5-13.
[11] Morice P, Juncker L, Rey A, et al. Ovarian transposition for patients with cervical carcinoma treated by radiosurgical combination [J].Fertil Steril, 2000, 74(10):743-8.
[12] Morice P, Haie-Meder C, Pautier P, et al. Ovarian metastases on transposed ovary in patients treated for squamous cell carcinoma of the uterine cervix:report of two cases and surgical implications [J].Gynecol Oncol, 2001, 83(5):606-7.
[13] Ishii K, Aoki Y, Takakuwa K, et al. Ovarian function after radical hysterectomy with ovarian preservation for cervical cancer [J]. J Reprod Med, 2001, 46(3):347-52.
[14] Kobayashi K, Furukawa A, Takahashi M, et al. Neoadjuvant intraarterial chemotherapy for locally advanced uterine cervical cancer:clinical efficacy and factors influencing response [J]. Cardiovasc Intervent Radiol, 2003, 26(2):234-41.
[15] D’Agostino G, Distefano M, Greggi S, et al. Neoadjuvant treatment of locally advanced carcinoma of the uterine cervix with epirubicin,paclitaxel and cisplatin [J]. Cancer Chemother Pharmacol, 2002, 49(1):256-60.
[16] Kuzuya K. Chemoradiotherapy for uterine cancer:current status and perspectives[J]. Int J Clin Oncol, 2004, 9(9):458-70.
[17] Chen HS, Gross JF. Intraarterial infusion of anticancer drugs:theoretical aspects of drug delivery and review of responses [J]. Cancer Treat Rep, 1980, 64(1):31-40.